drugset / Trial / NCT02276365

Bioavailability of BI 10773 and Pioglitazone in Healthy Male Volunteers

NCT02276365

Phase 1 Completed 20 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-labelTreatment

Summary

The objective of the study was to investigate whether there is a drug-drug interaction between BI 10773 and pioglitazone when co-administered as multiple oral doses. Therefore, the relative bioavailabilities of BI 10773 and pioglitazone were determined when both drugs were given in combination compared with BI 10773 and pioglitazone given alone.

Timeline

Start
2009-06
Primary completion
2009-07
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Empagliflozin Small molecule 50 mg Oral
Subject Pioglitazone Small molecule 45 mg Oral

Indications

No indication recorded.